Sabinene exhibits promising activity as a natural anti-virulence candidate that attenuates quorum sensing and biofilm-associated virulence factors in P. aeruginosa, warranting further investigation into its therapeutic potential.
Abstract
Recent studies have focused on developing innovative therapeutic interventions in response to the increasing antibiotic resistance reported in opportunistic pathogens such as Pseudomonas aeruginosa. Sabinene is a bicyclic monoterpene found in various essential oils. In this study, the anti-virulence activity of a technical-grade sabinene (77.6% sabinene, 22.3% β-pinene, GC purity; hereafter TGS) was evaluated against the biosensor strain Chromobacterium violaceum and a single clinical isolate of β-lactamase-producing Pseudomonas aeruginosa. The minimum inhibitory concentration (MIC) of TGS was 0.971 mg/mL. Sub-MICs of TGS (0.036 mg/mL and 0.108 mg/mL) demonstrated antibiofilm activity, with more pronounced inhibition at the higher concentration. Swarming motility, surface hydrophobicity, and cell aggregation were also reduced by TGS, while the metabolic activity of biofilm-embedded cells remained high (>89%) at sub-MIC concentrations. In addition, TGS inhibited exopolysaccharide (EPS) production by 66%, thereby disrupting biofilm matrix formation. Moreover, TGS inhibited key quorum sensing (QS)-associated virulence factors, including extracellular protease, rhamnolipids, and pyocyanin. Anti-QS activity was further corroborated phenotypically using the biosensor strain Chromobacterium violaceum. At 0.108 mg/mL, TGS inhibited violacein production (60%) and N-acyl homoserine lactone (AHL) generation. qRT-PCR analysis showed that the QS-associated genes lasI, lasR, and rhlI were downregulated following TGS treatment. These genes are required for the expression of several virulence factors, as they encode regulators and enzymes involved in QS signal transduction and AHL production. TGS exhibits promising activity as a natural anti-virulence candidate that attenuates quorum sensing and biofilm-associated virulence factors in P. aeruginosa, warranting further investigation into its therapeutic potential.
Background/Objectives: The rapid emergence of antimicrobial resistance (AMR) among pathogenic bacteria has necessitated the development of alternative therapeutic strategies that target bacterial virulence rather than cell viability. Methods: In this study, the flavonoid myricetin was systematically evaluated for its a...
Abdulrahman S. Bazaid, Nizar H. Saeedi, Mohammed M. Jalal et al.· Pharmaceutics· 0 citations
Pseudomonas aeruginosa employs quorum sensing (QS) to coordinate biofilm formation and virulence factor expression, positioning QS as a promising target for anti-infective interventions. This study evaluated the antibiofilm and antivirulence efficacy of 2-methoxy-1,4-naphthoquinone (MNQ), a natural naphthoquinone, agai...
Background/Objectives: The increasing antibiotic resistance of pathogenic bacteria has created an urgent need for new therapies that target virulence factors. Biofilm formation is a major determinant of bacterial pathogenicity and antimicrobial resistance. Methods: Biofilm formation assays (using crystal violet stainin...
Jimin Yoon, Ye-ji Kim, Ki-Young Kim· Antibiotics· 1 citation
Genome-informed glycan-utilization predictions identified substrates capable of producing probiotic metabolites that attenuate multiple P. aeruginosa virulence phenotypes, and Arabic gum shows particular promise for microbiome-based control of multidrug-resistant P. aeruginosa.
Rasha Elsayim, Monerah S. M. Alqahtani, Malak AlOsaimi et al.· Frontiers in Microbiology· 0 citations
The increasing prevalence of multidrug-resistant (MDR)
Pseudomonas aeruginosa
has reduced the effectiveness of conventional antibiotics and necessitated the development of alternative therapeutic approaches. Quorum sensing (QS), a bacterial cell-to-cell communication system that regulates virulence factor productio...
Akhter Ahmed Ahmed, F. A. Salih· BIO Web of Conferences· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.